Intravenous Dextrose in Patients With Diabetes
D5W is not appropriate as routine intravenous maintenance therapy in patients with diabetes. [1]
D5W is appropriate as part of targeted treatment when intravenous insulin is being continued for a hyperglycemic crisis and dextrose must be added to prevent hypoglycemia. [1]
D5W is not appropriate for treatment of symptomatic severe hypoglycemia. [2]
Indication for D5W During Hyperglycemic Crises
For diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), initial resuscitation uses isotonic saline. [1]
When plasma glucose falls below 250 mg/dL (13.9 mmol/L) during treatment, replacement fluids should be modified to include 5–10% dextrose in addition to 0.9% sodium chloride. [1]
D5W is the practical dextrose component used when the clinical goal is to allow continuation of insulin therapy while preventing hypoglycemia. [1]
Inappropriate Use as Routine Maintenance Fluids
D5W is primarily a dextrose delivery vehicle whose free-water effect can promote hypotonicity after dextrose is metabolized. [2]
Routine use of D5W as an intravenous fluid strategy for patients with diabetes (without a hyperglycemic crisis requiring insulin continuation or a hypoglycemia-treatment protocol) is not supported. [2]
D5W in Symptomatic Hypoglycemia
D5W should not be used to treat symptomatic hypoglycemia in severe presentations. [2]
Immediate treatment of symptomatic hypoglycemia should follow a protocol using rapid glucose replacement rather than relying on D5W. [2]
Medication/Infusion-Related Nuance
Use of dextrose-containing fluids is driven by concurrent insulin therapy requirements during DKA/HHS rather than by diabetes diagnosis alone. [1]
Treatment Thresholds for Adding Dextrose During DKA/HHS
Addition of dextrose is recommended when plasma glucose is <250 mg/dL (13.9 mmol/L). [1]
Practical Selection Algorithm
- Isotonic crystalloid (0.9% sodium chloride) is used for initial resuscitation in DKA/HHS. [1]
- Dextrose-containing fluid (5–10% dextrose added to 0.9% sodium chloride) is used when glucose falls below 250 mg/dL (13.9 mmol/L) to prevent hypoglycemia while continuing insulin. [1]
- D5W is avoided as a therapy for symptomatic severe hypoglycemia. [2]
Targeted Safe Use Statements
D5W is appropriate for preventing hypoglycemia during ongoing insulin therapy for DKA/HHS once glucose reaches <250 mg/dL (13.9 mmol/L). [1]
D5W is not appropriate as routine intravenous maintenance therapy for patients with diabetes without a specific treatment need. [2]
D5W is not appropriate for treatment of symptomatic severe hypoglycemia. [2]